None listed
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 19 years or older and under 80 years 2. Patients who visit the Department of Nuclear Medicine and are waiting for administration of radiopharmaceuticals 3. Patients who voluntarily agree to participate in this clinical study and provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with a history of allergy to radiopharmaceuticals 2. Patients with psychiatric disorders or a history of alcohol abuse or drug misuse 3. Patients deemed by the investigator to be unsuitable for participation in the study for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the Appropriateness of Smart Device-Based Biosignal Monitoring (Comparison with Conventional Biosignal Measurement Methods in Cases of Abnormal Findings);Questionnaire Evaluation for Patients Participating in Smart Device-Based Biosignal Monitoring | — |
Secondary
| Measure | Time frame |
|---|---|
| Prediction of patient prognosis using collected biosignal data. | — |
Countries
Korea, Republic of
Contacts
Public ContactSuyeon Hwang
National Cancer Center
Outcome results
None listed